News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
685,568 Results
Type
Article (39048)
Company Profile (279)
Press Release (646241)
Section
Business (203864)
Career Advice (1990)
Deals (35363)
Drug Delivery (85)
Drug Development (80799)
Employer Resources (168)
FDA (16088)
Job Trends (14804)
News (344544)
Policy (32438)
Tag
Academia (2530)
Alliances (49086)
Alzheimer's disease (1228)
Approvals (16020)
Artificial intelligence (130)
Bankruptcy (352)
Best Places to Work (11534)
Biotechnology (200)
Breast cancer (120)
Cancer (1081)
Cardiovascular disease (97)
Career advice (1660)
Cell therapy (232)
Clinical research (64239)
Collaboration (387)
Compensation (197)
COVID-19 (2530)
C-suite (94)
Data (1119)
Diabetes (152)
Diagnostics (6138)
Earnings (84817)
Employer resources (146)
Events (109470)
Executive appointments (310)
FDA (16623)
Funding (349)
Gene therapy (177)
GLP-1 (575)
Government (4326)
Healthcare (18668)
Infectious disease (2615)
Inflammatory bowel disease (106)
Interviews (308)
IPO (16298)
Job creations (3623)
Job search strategy (1417)
Layoffs (412)
Legal (7853)
Lung cancer (170)
Manufacturing (176)
Medical device (13174)
Medtech (13179)
Mergers & acquisitions (19140)
Metabolic disorders (401)
Neuroscience (1503)
NextGen Class of 2024 (6499)
Non-profit (4464)
Northern California (1476)
Obesity (231)
Opinion (179)
Patents (102)
People (56269)
Phase I (19950)
Phase II (28298)
Phase III (21095)
Pipeline (455)
Postmarket research (2553)
Preclinical (8491)
Radiopharmaceuticals (236)
Rare diseases (218)
Real estate (5890)
Regulatory (21519)
Research institute (2308)
Resumes & cover letters (349)
Southern California (1298)
Startups (3562)
United States (13445)
Vaccines (548)
Weight loss (167)
Date
Today (133)
Last 7 days (801)
Last 30 days (3813)
Last 365 days (35631)
2024 (32672)
2023 (40074)
2022 (51173)
2021 (55714)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37553)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (192)
Asia (37118)
Australia (6057)
California (3318)
Canada (1286)
China (247)
Colorado (144)
Connecticut (152)
Europe (79501)
Florida (458)
Georgia (116)
Illinois (341)
Indiana (196)
Kansas (96)
Maryland (575)
Massachusetts (2602)
Michigan (157)
Minnesota (272)
New Jersey (952)
New York (957)
North Carolina (701)
Northern California (1476)
Ohio (139)
Pennsylvania (843)
South America (1091)
Southern California (1298)
Texas (461)
Utah (90)
Washington State (360)
685,568 Results for "kempharm inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
KemPharm Issues Letter to Shareholders - January 24, 2023
KemPharm, Inc. today announced that Richard W. Pascoe, Chief Executive Officer of KemPharm, has issued a Letter to Shareholders.
January 24, 2023
·
12 min read
KemPharm Announces Corporate Name Change to Zevra Therapeutics
KemPharm, Inc. announced today that it changed its name to Zevra Therapeutics, Inc. (“Zevra”).
February 22, 2023
·
7 min read
Business
KemPharm Enhances Senior Management Team
KemPharm, Inc. announced that it has named Daniel Gallo, Ph.D., as Senior Vice President of Medical Affairs and Advocacy, and Abbi Maher, J.D., as Vice President of Legal Affairs.
January 31, 2023
·
4 min read
Business
KemPharm Announces Appointment of Christopher Posner as New Independent Director
KemPharm, Inc. today announced the appointment of Christopher Posner to serve on the Company’s Board of Directors.
November 29, 2022
·
6 min read
Deals
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. (“KemPharm”).
May 17, 2022
·
4 min read
FDA
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)
KemPharm, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted the Orphan Drug Designation to serdexmethylphenidate (SDX), KemPharm’s proprietary prodrug of d-methylphenidate (d-MPH), for the treatment of idiopathic hypersomnia (IH), a rare neurological sleep disorder.
November 18, 2022
·
6 min read
BioMidwest
KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company
KemPharm, Inc. announced changes to its Board of Directors and executive leadership team as part of the Company’s ongoing business transformation initiatives.
January 9, 2023
·
9 min read
Business
KemPharm announced its partnership with Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy
KemPharm, Inc. announced its partnership with the Hypersomnia Foundation , which engages, informs and champions the global community to improve the lives of people with idiopathic hypersomnia (IH) and related sleep disorders.
January 18, 2023
·
8 min read
Business
KemPharm Reports Third Quarter 2022 Results
KemPharm, Inc., a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, reported its financial results for the quarter ended September 30, 2022.
November 9, 2022
·
13 min read
Business
KemPharm to Report Third Quarter 2022 Financial Results
KemPharm, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, November 9, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the third quarter 2022.
November 1, 2022
·
2 min read
1 of 68,557
Next
